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Parkinson’s disease (PD) was first described 
200 years ago, and since then, the 
understanding of the pathological 
mechanisms and the development of 
treatments have been subjects of 
considerable research. The treatment of PD 
has been revolutionized twice: first by the 
pharmacological dopaminergic substitution 
by levodopa (L-DOPA)1 and later by deep 
brain stimulation of the subthalamic nucleus 
(STN DBS).2 Although L-DOPA is very effective 
at reversing the cardinal motor symptoms of 
PD, it leads almost inevitably to L-DOPA–
induced dyskinesias or motor fluctuations.3 
Prior to the advent of L-DOPA, stereotactic 
surgery for movement disorders had been 
introduced, and lesional surgeries provided 
substantial improvement in the 1950s 
despite the primitive imaging possibilities 
available at the time.2,4 However, the 
introduction of L-DOPA in 1968 brought 
stereotactic surgery to almost a complete 
stop.4 In 1987, Benabid et al. described the 
use of high frequency stimulation as a 
reversible lesion analogue5 and paved the 
way to clinical introduction of STN DBS as a 
PD treatment and subsequent popularization 
of the procedure.6 
 
STN DBS is a clinically effective treatment 
that has been extensively studied both 
clinically and in experimental animal models, 
but the precise mechanism of its effect 
remains enigmatous.7 Even the exact location 
of optimal electric stimulation within STN, or 
even outside the STN, is subject to continuing 
debate.8 
 
However, the available treatments offer only 
symptomatic relief, and no current treatment 
can slow or reverse the progression of PD.9,10 
Several possible treatments have been 
studied, and although many have been 
successful in experimental models, none has 
been uniformly effective in treatment of 
clinical PD. One reason for this non-success 
might be the fact that the dopaminergic 
degeneration is already substantial by the 
time of onset of PD symptoms, and by 5 
years after diagnosis, the dopaminergic 
system is practically devoid of dopaminergic 
neurites.11 Both potential neuroprotective 
treatment therapies and STN DBS are 
commonly offered to patients with over 5 
years of disease duration12, highlighting the 
requirement to develop neuroprotective 
treatments that would work in clinically 
realistic circumstances.13 
 
One promising class of neuroprotective 
agents are the neurotrophic growth factors 
(NTFs)14, which have shown positive results in 
post-hoc analysis in a subset of patients with 
shorter duration of disease.15 Because the 
treatment results with NTFs have been quite 
modest, NTFs are not expected to function as 
monotherapies in PD, providing a rationale to 
study the interactions of NTFs with 





REVIEW OF LITERATURE 
 9 
where no chemical exposure is evident, no 
familial history of PD exists, and no signs of 
atypical parkinsonian syndromes develop are 
generally referred to as sporadic Parkinson’s 
disease (sPD)42, although a complex interplay 
probably occurs between environmental and 
genetic factors.43 The inaccuracy of the initial 
diagnosis, and especially the relative inability 
to exclude the possibility of atypical 
Parkinsonian syndromes, is one the main 
reasons why invasive and experimental PD 
treatments often require a five-year follow 
up after the diagnosis. Some researchers 
have argued that this has led to suboptimal 
results in trials of potential neuroprotective 
and neurorestorative treatments.13 
 
PD is a progressive disease and the 
progression and the severity of the disease 
can be monitored with a scale originally 
published by Hoehn and Yahr.44 The time 
needed to reach the more advanced disease 
states45 can vary considerably.46 The life 
expectancy of PD patients is reduced16 
(mortality hazard ratio 1.5–2.7) and the risk 
of death is increased in patients who develop 
Parkinson-related dementia.47 Although 
dopaminergic drugs provide good 
symptomatic control, they do not slow the 
progression of the disease. Various 
treatments have been studied in order to 
modify disease progression but have had 
disappointing results.48 Among these 
therapies are the use of various neurotrophic 
growth factors (NTFs), which have shown 
successful results in animal studies but have 
generally failed clinical blinded trials.49 The 
quality of life (QoL) in Parkinson’s disease is 
decreased, especially in the later stages50 
where patients also become dependent on 
outside care. The non-motor symptoms, in 
particular, lead to a decreased quality of 
life.51 Some non-motor symptoms also fail to 
respond well to dopaminergic or other 
pharmacological treatments, especially in the 
later stages of PD.52 
 
The cost of the disease burden is high in PD 
patients: in 2010, direct costs per patient 
averaged $12,805 and indirect costs $10,046 
in the US53 and 5626€ direct and 5526€ 
indirect in Europe.54. This amounts to a 
disease cost for PD of over $14,4 billion 
yearly in the US alone and €13,9 billion in 
Europe. The current aging of the population 
is leading to overall increases in these costs, 
and neuroprotective therapies are now being 
promoted as potential ways to both increase 
the quality of life and decrease the economic 
cost of PD.55 
 
2.1.2 The dopaminergic system and the 
basal ganglia 
 
The dopaminergic system is one of the 
monoaminergic neuromodulatory systems in 
the brain,56 and it exerts wide tonic control 
on various functions in the central nervous 
system (CNS). The majority of dopamine 
neurons belong to either nigrostriatal or 
mesolimbic/-cortical pathways. The soma of 
nigrostriatal neurons are located in the 
substantia nigra pars compacta (SNpc) and 
they project axons to the striatum. The soma 
of the mesolimbic/-cortical dopaminergic 
neurons are located in the ventral tegmental 
area (VTA) and they project their axons to 
the limbic system and to the cortex. 
Dopamine and other catecholamines act as 
modulators of neural signaling rather than as 
synaptic transmitters and they regulate 
various important behaviors.57 
 
Understanding the function of dopamine in 
the brain also requires that the anatomy and 
physiology of the dopaminergic system, basal 
ganglia, and cortico-striato-thalamocortical 
systems (CSTS) to be described. The CSTS 
comprises complex 58-59 and parallel 
networks 60 that contribute to the regulation 
of a wide variety of functions and behaviors, 
ranging from motor functions to limbic and 
associative functions. The parallel networks 
have some shared and some distinct 
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components.60 The following description 
focuses mainly on the motor CSTC, which is 
of greatest importance in understanding the 
cardinal motor symptoms of PD.  
 
A widespread glutamatergic excitatory 
projection extends from the cortex to the 
striatum, where cortical fibers connect with 
striatal medium spiny neurons (MSN) that 
receive either excitatory (D1, direct pathway) 
or inhibitory (D2, indirect pathway) 
dopaminergic input from the substantia nigra 
pars compacta (SNc).61 The main output 
pathway of the striatum is the globus pallidus 
interna (GPi) and substantia nigra pars 
reticulata (SNr) for the direct pathway and 
the globus pallidus externa (GPe) for the 
indirect pathway. The main output of GPe is 
to the subthalamic nucleus, and the GPe 
receives reciprocal output from the STN; 
projections also extend to the SNr and GPi. 
STN also has output to the SNr/GPi, where 
the direct and the indirect pathways 
converge. The SNr/GPi have their main 
outputs to the thalamus, which in turn 
projects back to both the striatum and the 
cortex to create the CSTC loop (Figure 1). This 
canonical model of the CSTC networks have 
been challenged to provide a better 
explanation of some phenomena, but for 
understanding the overall structure and 
function the canonical model has still held its 
value.59 Major alterations and dysfunctions in 
any part of this network can lead to 
disruption in the overall function of the CSTC 
network. However, this also provides the 
opportunity to treat a dysfunctional CSTC 
loop by delivering treatments that affect only 
anatomically isolated components of the 
loop; this is the basis for the stereotactic 
functional neurosurgical treatments 
described in detail later (chapter 2.2). 
 
Neural signaling in the CSTC has been studied 
extensively at both the cellular and 
intracellular levels in different anatomical 
locations. The signaling in the main 






















Figure 1 The canonical model of CSTC network organization. 
D1 = D1-receptor positive medium spiny neurons, D2 = D2-receptor positive medium spiny neurons, GPe = globus 
pallidus externa, GPi = globus pallidus interna, STN = subthalamic nucleus, Excitatory connections in red and 
inhibitory connections in blue. Adapted and modified from Lanciego 201259 
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PD and animal models of PD.72 Currently, one 
of the most attractive theories is the 
accumulation of pathological forms of α-
synuclein in the gastric neurons related to 
gut microbiota.75 The α-synuclein-related 
changes in the gastric neurons are thought to 
be propagated to the CNS supposedly by 
ascending along the vagus nerve. The now 
classical model is the Braak theory,70 which 
describes the ascending propagation of α-
synuclein pathology (LB and LN) starting from 
the caudal brainstem and eventually 
affecting the whole brain, including the 
cortex, at the most advanced stages.  
 
The effects of dopaminergic cell loss on the 
basal ganglia signaling has been described in 
detail at both the cellular level76,77 and brain 
network level, especially for the functionally 
most important CSTC pathways. 78,58,79 In 
Parkinson’s disease, the dopaminergic output 
in striatonigral neurons is decreased and this 
leads to compensatory changes in the motor 
CSTC. The main effect of decreased 
dopaminergic tone in the striatum has been 
shown to be a shift in balance toward 
increased activity in the so-called indirect 
pathway compared to the direct pathway.80 
The overall effect of the indirect pathway is 
inhibitory, whereas the overall effect of the 
direct pathway is excitatory. The inhibitory 
effects of the indirect pathway are mediated 
by the increased activity of the subthalamic 
nucleus (STN) in response to dopamine 
depletion.78,80,81.  
 
The STN has been suggested to function as a 
general inhibitory brake in the brain by 
decreasing thalamocortical excitation 
through increases in the inhibitory drive of 
the GPi and SNr to the thalamus.82-84 L-DOPA 
corrects some of the related pathological 
changes, but intermittent L-DOPA 
administration in particular can lead to 
overactivity of the thalamocortical pathway 
and the appearance of L-DOPA-induced 
dyskinesias (LID) seen clinically, especially in 
the more advanced stages of PD85. The 
mechanisms of L-DOPA-induced dyskinesias 
have been of considerable research interest 
both clinically and pre-clinically.85,86 One of 
the main phenomena related to LIDs is the 
hyperactivation of the D1-positive MSNs of 
the direct pathway, which is reflected by an 
increase in DARPP-32(thr34) phosphorylation 
after chronic and intermittent administration 
of L-DOPA, resulting in a concurrent increase 
in LIDs.87 The severity of LIDs in experimental 
rodent models has been assessed on a rating 
scale (0–4) based on the duration and 
severity of the involuntary dyskinetic 
movements.88 The dyskinesias are further 
divided into orofacial, axial, front limb, and 
locomotive subtypes.  
 
Overall, the pathobiology of PD can be 
crudely divided into pathological changes 
related to or causing the dopaminergic cell 
loss and the progression of the disease and 
the changes related to the effects of 
decreased dopaminergic signaling, especially 
in the striatum, and the mechanisms of 
symptom formation in PD.  
 
2.1.4 Experimental models of PD 
 
The study of pathological mechanisms and 
treatments of PD requires the use of 
experimental animal models. Neurotoxin-
induced rodent models have been the 
mainstay in PD animal research89, although a 
number of non-human primate studies have 
been conducted.90 Basic research has also 
been conducted on zebra fish91 and 
drosophila,92 among other species.  
 
The most commonly used animal models are 
toxin models (6-hydroxydopamine: 6-OHDA 
and MPTP) that produce a rapid 
dopaminergic cell death and dopamine 
depletion.93 Both 6-OHDA and MPTP are 
known to aggregate in dopaminergic cells, 
where they cause cell death by inducing the 
formation of reactive oxygen species (ROS) 
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behavior, that this behavior is not a normal 
behavior exhibited naturally by the rats, and 
that the results are not directly translatable 
to results in clinical PD. 95 Other behavioral 
tests that do not rely on pharmacologic 
stimulation are the cylinder test106 and the 
staircase test,107 among others; these tests 
measure different aspects of motor behavior. 
The cylinder test measures front limb activity 
by placing the rat in a transparent cylinder 
and counting the number of front limb 
touches with the vertical wall during 
exploration and comparing the use of front 
limbs as a measure of asymmetry. The 
cylinder test relies on rat exploratory activity, 
which might be affected by repetitive 
application of the cylinder test or 
disturbances in the experiment room. 106 The 
cylinder test, however, does not require 
training of the rat before testing. The 
staircase test measures skilled front limb use 
by measuring the number of food pellets that 
the rat is able to pick with each front limb. 
The drawbacks of the staircase test are that 
the rat needs training before testing and 
must be fasted before individual training or 
testing sessions. Although these tests provide 
experimental measure of motor deficits 
related to dopamine depletion, they do not 
necessarily replicate the more complex 
situation in clinical PD. Overall, multiple 
behavioral tests can be employed in 
experimental testing to produce more 
reliable results. 89 
 
2.1.5 Treatment strategies for PD 
 
The available treatments for PD can provide 
effective symptom control, especially for the 
motor symptoms, but no therapies to alter 
the disease course are yet available.108 The 
current treatment strategies for PD depend 
on the age of the patient, the severity of the 
symptoms, and the course of the 
disease.109,110 The most effective 
pharmacological treatment of the motor 
symptoms of PD are orally administered 
dopaminergic drugs, which can be either 
dopamine agonists, MAO-B inhibitors, or the 
more potent L-DOPA. In patients with mild to 
moderate motor symptoms and age under 60 
years, treatment can be started with 
dopamine agonists or MAO-B instead of L-
DOPA111,112, or even non-dopaminergic drugs 
such as acetylcholinesterase inhibitors or the 
NMDA antagonist amantadine.113 Dopamine 
agonists or L-DOPA are usually offered to 
patients with more severe motor symptoms 
and impairment of activities of daily life. L-
DOPA is combined with drugs that inhibit the 
peripheral (DOPA decarboxylase inhibitors, 
carbidopa, and benserazide) and the central 
(CNS) (COMT inhibitor, entacapone, or 
opicapone) metabolism of dopamine. L-DOPA 
can cause intolerable dyskinesias and motor 
fluctuations 114 even a few months after 
starting this medication,115 thereby limiting 
its long-term effectiveness. Attempts can be 
made to manage the motor fluctuations 
medically by adding adjunctive medications, 
such as dopamine agonists, MAO-B 
inhibitors, and amantadine, or by altering the 
L-DOPA dosing regimen.116 Apomorphine, a 
strong D1- and D2-agonist, is an option for 
some patients with motor fluctuations.117,118 
 
Patients who develop severe dyskinesias or 
motor fluctuations but retain the L-DOPA 
treatment effect and do not develop severe 
cognitive or psychiatric comorbidities are 
candidates for invasive treatments of PD, 
such as deep brain stimulation (DBS) and L-
DOPA infusion.116,117 However, the 
appearance of additional clinical features can 
sometimes suggest a diagnosis of an atypical 
parkinsonian syndrome36 38, where invasive 
treatments are not generally suitable. 
 
Various disease course altering therapies 
have been trialed in PD. The effect on the 
disease course can be divided to 
neuroprotection, slowing or stopping the 
degenerative processes, and 
neurorestoration by reversal of the effects of 
REVIEW OF LITERATURE 
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degeneration (e.g., by activating regenerative 
processes). 119 Currently, none has been 
effective in clinical controlled trials.48 
However, trials are ongoing in the search for 
effective disease-course altering therapies.120 
So far, the sole aim of treatments for PD is 
symptom control—and the avoidance of side 
effects of the treatment. 
 
2.2 Deep brain stimulation 
 
2.2.1 History of stereotactic and functional 
surgery and Deep Brain Stimulation 
 
The English pioneer of neurosurgery Sir 
Victor Horsley and the mathematician-
surgeon Robert Clarke are commonly 
acknowledged as the first to have introduced 
the concept of stereotaxis. In 1908,121 they 
presented an apparatus that used a three-
dimensional Cartesian coordinate system to 
introduce probes and needles accurately into 
targets deep in the brains of experimental 
animals.122,123. They also described the use of 
electrical currents to produce a controlled 
and local lesion in the brain and reported 
their results of electrolytic lesions in the 
monkey dentate nucleus of the cerebellum 
using bony landmarks to define a 3-
dimensional coordinate system. In 1947, 
Spiegel and Wycis were the first to report the 
use of stereotaxy in the human brain, calling 
their technique “stereoencephalotomy.”124 
Instead of bony landmarks of the skull, they 
used intracerebral landmarks acquired by 
ventriculography, thereby providing relatively 
accurate navigation around the third cerebral 
ventricle. Their procedure originally required 
the use of pneumoencephalography125—the 
injection of air into the intrathecal space and 
eventually to the cerebral ventricles to 
provide contrast to visualize the anatomical 
landmarks. The technique for lesioning was 
further enhanced by improvements in 
thermal radiofrequency lesioning126,127,128 
and intraoperative stimulation for better 
localization of neuroanatomic targets. 129,130 
Even though there were no frames available 
commercially, the early years after the 
introduction of human stereotaxis were an 
especially fruitful period of both technical 
innovation and advancements in clinical 
neuroscience. 131 The introduction of the 
center of arc principle by Leksell132 had a 
particularly strong influence on the future 
design of later commercially available 
frames. Some of the other influential frame 
designs were the Talaraich frame and the 
Todd-Wells apparatus (later developed to 
become the Cosman-Roberts-Wells frame).4 
 
Prior to the introduction of proper 
stereotactic systems, various other methods 
were developed to provide relatively 
accurate strategies for deep intracerebral 
lesioning. The most famous example is 
perhaps the standard leucotomy described in 
1935 by the Portuguese neurosurgeon 
Almeida Lima as a method for limbic 
leucotomy that later became popularized as 
frontal lobotomy.133,134 Although the 
methods were comparatively accurate for 
the time, none of these methods came even 
close to the accuracy and precision of the 
actual stereotactic systems. Sadly, the 
methods for lobotomy became even less 
precise while its use was popularized, and it 
was applied irresponsibly.135 
 
The first patients treated with stereotactic 
procedures were movement disorder 
patients124. However, the surgery for 
Parkinson’s disease predates the introduction 
of human stereotaxis. A wide variety of 
surgical techniques and targets were trialed 
(including corticotomy136,137 and 
posterolateral cordotomy138) and early 
attempts were also made to target the 
extrapyramidal system for symptom relief.139 
The safety of these surgeries was appalling, 
with unacceptably high mortality rates. 
Together with advancement of clinical and 
pre-clinical neuroscience, these early 
attempts provided potential targets for later 
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debilitating side effects of L-DOPA, such as 
dyskinesias (LID) and motor fluctuations (“on-
off” phenomenon of L-DOPA effect), were 
indisputable.23 Posteroventral pallidotomy, 
as described by Laitinen, provided effective 
reduction in LID, in addition to symptom 
reduction of the core symptoms of PD159, 
although this was later contested.160 During 
the inactive years of movement disorder 
surgery, the ability to locate the anatomical 
targets with microelectrode recording had 
also improved,161-163 as had the use of 
computed tomography (CT) and magnetic 
resonance imaging (MRI) for better 
visualization of the anatomy.151 The result 
was that pallidotomy started to regain 
popularity and the number of movement 
disorder surgeries increased worldwide.143 
Pallidotomy could be used as a unilateral or a 
staged bilateral operation, although the 
bilateral pallidotomy was reported to have 
significant risks of severe side effects that 
included dysarthria, dysphonia, and cognitive 
decline;143,164 consequently, the benefits of 
the second contralateral lesion remained 
questionable. Pallidotomy is not widely used 
at present, but unilateral pallidotomy has still 
been advocated by some as a more tolerable 
option compared to bilateral subthalamic 
stimulation, especially in older and more 
fragile patients, 144,165 although many 
controversies exist.152 Additionally, at the 
beginning of the 1990s, alleviation of the 
motor symptoms of PD was shown in 
response to both chemical81 (ibotenic acid) 
and thermal166 lesioning of the STN, thereby 
verifying earlier results achieved by the 
creation of larger subthalamic area 
lesions.147,153 Although STN lesions (STNL) are 
associated with dyskinetic complications and 
even hemiballismus, modern results suggest 
that unilateral STNL might at least be a 
relatively safe alternative167, and that 
inclusion of the zona incerta (ZI) in the lesion 
could avoid dyskinesias.168 
 
Despite some early, and mostly short-term, 
attempts at therapeutic stimulation,169-171 the 
role of electrical stimulation in movement 
disorder surgery was viewed mainly as an 
intraoperative method to verify anatomical 
targets until the late 1980s.172 Meanwhile, 
implantable stimulators had been developed, 
mainly for spinal cord stimulation for pain 
treatment.173 This changed drastically after 
the reports of cessation of tremor during 
thalamotomy operations with test 
stimulation frequencies over 100 Hz by 
Benabid174 and even earlier by Brice, who 
also reported 5 and 6 month results of two 
patients with implantable devices but 
external generators.175 Benabid carried out 
experimental animal studies to show the 
effect of subthalamic deep brain stimulation 
(STN DBS) in a primate MPTP model of PD.176 
This led to clinical trials of STN DBS for PD5 
and the encouraging results awakened a new 
period of wider acceptance of surgical 
treatments for movement disorders. Since 
higher stimulation frequencies (>100 Hz) had 
a net effect similar to lesioning the targets, 
stimulation could now be used in a reversible 
manner to replace lesions.177 The earlier 
success of pallidotomy led to trials of GPi 
DBS,178-180 which proved to be an effective 
stimulation target for the reduction of L-
DOPA-induced dyskinesias in PD,181 in 
addition to being an effective target for 
dystonias.182,183 The relative efficacy of STN 
DBS and GPi DBS has been studied in 
randomized controlled trials184-190 and 
subsequent meta-analyses191,192 showed that 
both targets lead to significant 
improvements, but only STN DBS has the 
possibility of reducing the need for 
dopaminergic medication. This implies that 
only STN DBS has a significant direct effect on 
PD symptoms, despite the earlier reports 
that pallidotomy reduced PD symptoms both 
in the pre-L-DOPA era146 and in the DBS 
era.193 Since its introduction, DBS has gained 
significant worldwide acceptance and 
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widespread use, especially for the treatment 
of advanced PD.6 
 
2.2.1.1 A Linguistic notion 
 
The proper use of the words “stereotaxis” 
and “stereotactic” has been historically 
controversial. Stereo and taxis are derived 
from Greek, while tactic is a Latin word for 
touch. Despite this combining of two 
different languages in a single word, the 
word stereotactic and its derivatives continue 
to be used. The use of the word stereotactic 
has been suggested to be reserved for 
human stereotaxis, while the use of 
stereotaxic is suggested for animal 
techniques.194 
 
2.2.2 Clinical use of Deep Brain Stimulation 
in PD 
 
Several guidelines or recommendations have 
been published on the use of DBS for PD.195-
196,197 Generally, the use of DBS has been 
confined to patients who have already 
developed LIDs or motor fluctuations.195,197 
The prerequisites for STN DBS are remaining 
effectiveness of L-DOPA 198 195, no dementia, 
no significant psychiatric issues, and an 
ability to cope with the stimulator hardware 
and programming.197 There have been 
suggestions and attempts to offer DBS also at 
earlier stages199-201, and anecdotally, even 
prior to commencing L-DOPA. An earlier 
application of DBS has been suggested, 
especially in younger patients who are 
especially prone to develop severe LIDs.199 
The average time for a patient to proceed to 
DBS has remained high, at up to 10–15 years 
after diagnosis.200 Although, in some cases, 
this long delay can reflect the slow disease 
progression by individual patients, there 
might still be a tendency to hold DBS as a 
last-resort therapy. On the contrary, it is 
commonly accepted that a follow-up period 
of 4–5 years is needed to ensure that PD 
diagnosis is confirmed and progressive 
supranuclear palsy and multisystem atrophy 
can be excluded.12,195,202,203 Currently, other 
alternatives are available for patients with 
unsatisfactory L-DOPA medication effects: 
the most important of these are continuous 
intrajejunal L-DOPA-carbidopa gel infusion 
via an inserted percutaneous gastroenteric 
tube204 and subcutaneous apomorphine. 
197,205 Continuous L-DOPA infusion has been 
shown to reduce dyskinesias and motor 
fluctuations,197,204 while apomorphine might 
be especially effective in treating non-motor 
symptoms during off periods.197,205 These 
therapies are offered to partially overlapping 
populations, although patient characteristics 
and additional local practices can influence 
which therapy is favored over others.206 
 
In current clinical practice, two main 
stimulation targets with their variations are 
used to achieve better control of the cardinal 
symptoms of PD: the subthalamic nucleus 
(STN) and globus pallidus interna (GPi).192 
Additionally, the Vim nucleus of the thalamus 
can be used to treat parkinsonian tremor, but 
it is more commonly used to treat essential 
tremor as it does not affect the other motor 
symptoms of PD.207 However, some studies 
have reported that stimulation of the 
posterior subthalamic area between the 
classic STN target and Vim can provide better 
tremor control in some patients and has 
some effect on other motor symptoms.208,209 
A schematic presentation of the anatomical 
targets is shown in Figure 2. Other DBS 
targets have also been trialed in PD.210 Both 
STN and GPi DBS are effective treatments, 
but only STN DBS produces direct 
improvement in PD symptoms and better 
reduction of dopaminergic medication, while 
GPi DBS leads to better improvement of LIDs 
and mood, with both targets providing 
similar overall benefit.192 The side effect 
profiles seen with these targets differ: STN 
DBS is known to produce more cognitive and 
psychiatric side effects, in addition to the 
more commonly seen blurring of 
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steering of stimulation have been developed 
to achieve better therapeutic windows 
between symptom control and side effects. 
230,234 
 
The stimulation parameters are usually 
optimized by a movement disorder 
neurologist and the PD drug treatment is 
adjusted231,235 with the aim of decreasing the 
L-DOPA dose or, rarely, the complete 
cessation of dopaminergic drugs. The 
stimulation amplitude, frequency, pulse 
width, and active electrodes can be adjusted 
by programming the implanted pulse 
generator with an external programming 
device. The optimal stimulation parameters 
are usually found within 6 months after the 
implantation.236 The implantable pulse 
generator requires a surgical change if the 
battery becomes depleted, which is seen, on 
average, in 3.5-5 years.237 The battery life 
strongly depends on the individual 
stimulation parameters. As with any 
implantable devices, the DBS hardware can 
also become infected, which generally 
requires at least partial removal of the 
electrodes, although treatment with 
antibiotics only is sometimes successful.238 
Hardware-related problems have been 
reported as the most common type of 
complication.239 
 
A recent meta-analysis found seven clinical 
trials comparing STN DBS versus best medical 
therapy (BMT).240 However, none of these 
trials included sham operations and only one 
trial included delayed activation of 
stimulation at three months but without any 
blinding.241 Additionally, the studies varied in 
design and follow-up times, which ranged 
from 3 months to five years (Table 2). The 
earliest randomized study with six-months of 
follow-up found reduced UPDRS-III scores at 
the medication OFF state, significantly 
improved quality of life, and reductions in 
troublesome dyskinesias.185 However, the 
number of serious side effects was higher in 
the STN DBS treated group while treatment-
related side effects were overall more 
common in the BMT group. Previous 
research reporting on cognitive and 
psychiatric side effects of STN DBS further 
verified that the improvements in motor 
symptoms and quality of life were not related 
to an overall deficit in cognitive functioning 
but to a selective decrease in frontal 
cognitive functions shown mainly by verbal 
fluency tests and variations of the Stroop 
test.242 Additionally, anxiety was also 
improved. A later large multicenter open-
label study with a well-controlled 
randomization protocol demonstrated similar 
improvements in QoL and motor function at 
1 year, even when apomorphine treatment 
was readily available for both groups.243 A 
direct comparison of STN DBS against 
apomorphine treatment with a very long 5-
year follow-up, although without formal 
randomization and low number of patients, 
showed superior effects of STN DBS, 
especially for dyskinesias.244 Additionally, the 
adherence to the assigned therapy was 
better in the STN DBS group. The effect of 
STN DBS in earlier stage PD was originally 
compared in a smaller trial245 followed later 
by the EARLYSTIM trial with 2-year follow-
up.199 Although the smaller initial trial 
showed exceptionally good results on 
UPDRS-III in early PD, this effect was not fully 
replicated by the later, much larger trial.199 
However, because of the stringent use of 
blinded scoring of videos for UPDRS-III scores 
(apart from rigidity) under several treatment 
conditions, the EARLYSTIM trial provides 
perhaps the most robust evidence available 
for the efficacy of STN DBS over BMT on the 
motor symptoms of PD, since STN DBS is 
subject to the placebo effect.246 Even though 
the EARLYSTIM trial showed a higher number 
of serious side effects in the STN DBS group, 
the number of serious stimulation- or 
medication-related side effects was lower for 
STN DBS than for BMT. 
 

REVIEW OF LITERATURE 
 23 
DBS patients have been reported to suffer 
from long-term stimulation-induced 
dyskinesias.253 
 
Considerable literature exists regarding the 
optimal anatomic target for STN DBS. Some 
candidates for the optimal target reside 
either on the dorsal border of STN254 or 
outside the STN (e.g., the zona incerta).255 A 
large single-center study that analyzed 262 
STN DBS patients suggested better 
improvement when the electrodes were 
placed in the central associative area of the 
STN, as cognitive decline was found with 
more ventral and posterior electrodes.256 
Analysis of electrode repositioning in patients 
with poor symptom control suggested that 
sensorimotor STN might be the optimal 
target.257 However, no consensus has yet 
been reached regarding the optimal target, 
although most specialists in the field place 
their preferred site for active stimulation 
inside the STN.8 
 
The stimulation current also spreads to larger 
areas, so the stimulated area can include 
several anatomic structures, which affects 
the balance of therapeutic effects and 
unwanted side effects. Several anatomical 
structures have been related to both 
therapeutic and adverse effects of STN DBS. 
The posterior subthalamic area,208 Vim,258 
and the dentato-rubro-thalamic tract259 are 
known targets for parkinsonian and essential 
tremor located posterior to the STN. 
However, these targets are usually 
considered as separate targets from STN. The 
ansa lenticularis and lenticular fascicularis 
(field H2 of Forel) connect the GPi to the 
thalamus, as both run supero-medial to the 
STN in the subthalamic area and are 
separated from each other by the zona 
incerta and connected medially to form the 
thalamic fasciculus (field H1 of Forel).260 The 
limbic STN, as the medial part of the STN, has 
been suggested to cause the psychiatric side 
effects of STN DBS.261,262 However, the 
medial forebrain bundle running close to the 
medial STN has also been suggested to 
convey some of the psychiatric side effects of 
STN DBS.263 Both the pars reticulata and pars 
compacta parts of the substantia nigra are 
located inferomedially to the STN, and the 
simultaneous use of stimulation of SNpr 
during STN DBS has been studied to alleviate 
refractory gait disturbances.264 The spread of 
current to the corticospinal and corticobulbar 
tract axons located in the cerebral peduncle 
can cause contralateral muscle 
contractions.265,266 
 
The medial lemniscus is located in the 
posterior subthalamic area, and it conveys 
sensory axons from the spinal cord to the 
sensory thalamus. The spread of current to 
the medial lemniscus causes paresthesias.267 
The nucleus ruber can be inadvertently 
stimulated by medial contacts to produce 
gait and postural ataxias.268 Projections from 
prefrontal areas (i.e., the frontal eye fields) to 
the oculomotor nuclei run partly in the 
subthalamic area, and their stimulation can 
cause conjugate eye deviation that is 
commonly controversive and habituates 
easily.268 This contrasts with third nerve fiber 
stimulation from a more medial stimulation, 
which is ipsiversive, manifested only in the 
ipsilateral eye, and does not habituate. 
Blurring of speech, or dysarthria, can occur 
with electrodes located within or outside the 
STN.269 During intraoperative test 
stimulation, these side effects can be used to 
confer the anatomic location of the electrode 
and help with decision making related to the 
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human PD patients, so these have to be 
addressed in animal experiments.  
 
DBS conducted with the clinically most 
commonly used frequencies of over 100 Hz 
generally produces very similar effects to 
similarly located lesions; however, the exact 
nature of the impact of DBS on the different 
neural components has been the subject of 
considerable discussion and remains 
incompletely understood.304,305 Furthermore, 
different neural structures (neuron somas 
and axons) probably respond differently to 
stimulation.299 
 
The overall electrophysiological effect of STN 
DBS has been proposed to be a balancing of 
an abnormally functioning neural network by 
jamming the abnormal bursting activity in the 
STN. 306 The effects of STN DBS on other 
components of the motor CTSC have been 
studied extensively: STN DBS has been shown 
to disrupt the electrophysiology of the GPi307 
and thalamus 308 and the excitability of the 
motor cortex,309,310 to decrease the 
pathological beta-band synchronization of 
the motor CSTC,311 312 and to reduce the 
GABA content in the ventral anterior nucleus 
of thalamus in a manner similar to L-DOPA.313 
 
In 1986, STN HFS was reported to affect 
dopamine release, but the results were 
controversial: a significant increase was 
noted in DA in the SNpc but the striatal DA 
levels decreased.314 Later studies reported 
increases in the levels of the striatal 
dopamine metabolites, DOPAC and HVA, 
without any increase in the striatal DA in 
both native and 6-OHDA-lesioned rats.315,316 
The inhibition of dopamine uptake by 
nomifensine revealed an increase in striatal 
DA during STN HFS in striatum 6-OHDA-
lesioned rats.317 Interestingly, small changes 
in the exact position of the electrode within 
DBS has been reported to either increase or 
reduce dopamine release in the striatum in 
non-human primates.318 However, despite 
some encouraging results,319 STN DBS does 
not seem to increase striatal DA in the 
human striatum.320 
 
The levels of glutamate and GABA are 
reported to increase in the SNpr but only the 
levels of glutamate increase in the GPe.321 
This increase of glutamate in SNpr has been 
related to stimulation-induced dyskinesias,322 
and a broad-spectrum glutamate antagonist 
was able to prevent stimulation-induced 
dyskinesias. Interestingly, in the same study, 
the GABA levels in the SNpr were reported to 
increase only when stimulating with a low 
amplitude that did not induce dyskinesias. 
However, the increase in SNpr glutamate and 
GABA persisted after stopping the STN HFS, 
underscoring that additional mechanisms are 
involved in the behavioral effects of STN HFS. 
 
STN HFS-induced rotations are reduced by 
intrastriatal injections of D2 antagonists but 
not by D1 antagonists in rats.323 In a 6-OHDA 
hemiparkinsonian rat model, STNL decreases 
the phosphorylation of thr34 in DARPP-32 
that is related to L-DOPA-induced dyskinesias 
caused by intermittent L-DOPA 
administration, although STN had only a 
minor effect on dyskinesias.86 In animal 
models, STN DBS induces changes in striatal 
gene expression279 and, interestingly, 
increases the striatal BDNF levels in native 
but not in 6-OHDA lesioned rats after two 
weeks of continuous stimulation.324 
 
Overall, STN DBS appears to have a 
widespread effect on all components of the 
motor CTSC that can be seen in various facets 
of neural functioning, ranging from electrical 
activity to gene expression. 
 
2.4 Neurotrophic growth factors 
 
Neurotrophic factors (NTFs) are secreted 
neuropeptides or proteins that are found in 
the CNS and the PNS, where they regulate 
the growth, survival, and function of 
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neurons.325-327 Nerve growth factor (NGF), 
discovered in 1956, was the first NTF to be 
found. 327 NGF binds to the tropomyosin 
kinase receptor A trkA, a transmembrane 
protein that mediates the effects of NGF on 
intracellular trophic signaling pathways.327  
 
The glial derived neurotrophic growth factor 
(GDNF) family comprises the proteins GDNF, 
neurturin, artemin, and persephin.325 GDNF 
exerts its effects by binding to a complex 
comprising the GDNF family receptor-α and 
receptor tyrosine kinase, both of which are 
expressed by dopaminergic neurons. 328 
GDNF and neurturin are neuroprotective in 
vitro and in vivo in Parkinson’s disease 
models. 14 GDNF reduces ROS formation in 6-
OHDA PD models.329 Neurturin binds to the 
naturally occurring heparan sulfate 
proteoglycan in the brain.330 Additionally, 
GDNF, GDNF family receptor-α and receptor 
tyrosine kinase have wide effects throughout 
virtually all cell types and organs in the 
body.325 
 
A novel neurotrophic factor, conserved 
dopaminergic neurotrophic factor (CDNF, 
also originally termed cerebral dopaminergic 
neurotrophic factor and used synonymously), 
and later, a related mesencephalic astrocyte 
derived neurotrophic factor (MANF) were 
described with qualities differing from the 
GDNF family.326 The CDNF/MANF family NTFs 
have no known receptor, but they probably 
exert their effects in the cytosol or the 
endoplasmic reticulum of neurons. Unlike 
GDNF and NRTN, neither CDNF nor MANF 
binds to heparin sulfate proteoglycans in the 
brain and this feature has been related to 
their better diffusion in the brain 
parenchyma.331 CDNF and MANF are both 
neuroprotective and neurorestorative in in 
vitro and in vivo models of PD. Recently, 
CDNF has shown a neuroprotective 
interaction with GDNF332 and with MANF333. 
 
Preclinical studies have examined the effects 
of administration of NTFs as single injections 
or continuous infusions of the proteins 
themselves or viral constructs.14 Neurturin 
variants have also been studied, in part, to 
overcome the problem of diffusion in the 
brain.334 
 
2.4.1 Clinical trials of neurotrophic growth 
factors 
 
An initial open label clinical phase I trial335 
and a phase II trial336 of continuous infusions 
of GDNF protein to the putamen showed a 
positive effect on PD symptoms. However, 
this was not replicated in a subsequent 
RCT.337 Some patients in these trials 
developed anti-GDNF antibodies and the 
primate models developed cerebellar 
atrophy soon after the GDNF therapy was 
stopped.338 Several possible reasons for the 
failure of GDNF therapy were 
suggested.328,339 A RCT of an AAV2-NRTN 
construct administered bilaterally to both the 
SNpc and putamen340 revealed no difference 
in the motor symptoms of PD (UPDRS-III). 
However, a statistically significant difference 
was noted in two of the secondary end point 
complications of therapy (UPDRS-IV) and in 
the time at home without troublesome 
dyskinesia at 15 months after the injections 
when compared to sham surgery. Overall, a 
recent meta-analysis found no proof of an 
effect of NTFs on PD.341 
 
Interestingly, a statistically significant 
improvement was noted in the motor 
symptoms compared to baseline in both 
groups, and the patients who received 
neurturin-AAV therapy less than 5 years after 
PD diagnosis had a statistically significant 
benefit according to a post-hoc analysis.13 
This effect was found also in a reanalysis of a 
previous Phase II study. However, post-
mortem analysis revealed increases in TH 
level around the injection sites, suggesting 
that limited diffusion of NTF or AAV-NTF 
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constructs could explain, at least in part, the 
negative results of the clinical trials.13,342 This 
limitation could possibly be overcome by 
using NTFs with better capability of diffusing 
in the brain, such as CDNF, or using smaller 
targets in the dopaminergic system, such as 
the SNpc. 
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3 AIMS OF THE STUDY 
 
STN DBS has been shown to be effective as a treatment in clinical and experimental PD, but the 
optimal clinical target, behavioral effects in animal models, and neuroprotective potential remain 
incompletely described. Various NTFs have shown effectiveness in partial dopaminergic 
degeneration models of PD, but the effects in late stage models have been mostly unexplored. 
Furthermore, in the late stages of PD where dopaminergic cell death is almost complete, the 
possibilities of neurorestoration are limited. The capabilities of NTFs in enhancing the effect of STN 
DBS have not been previously studied. 
 
The specific aims of the study were: 
 
I) To better describe the behavioral effects of STN DBS in a rat 6-OHDA model of late 
stage PD. 
II) To further analyze the therapeutic effect of clinical STN DBS and compare different 
methods of electrode location. 
III) To study the effects of the combination of CDNF and STN DBS in an animal model of 









































The animal experiment designs and 
procedures in publications I and II were 
approved by the Committee for Animal 
Experiments of the University of Helsinki, by 
the chief veterinarian of the County 
Administrative Board for 2008–2010, and by 
the National Animal Experiment Board for 
2011–2015. Animal experiments were 
conducted according to EU regulations (EU 
Directive 2010/63/EU) and Finnish legislation 
(Finnish Act on the Protection of Animals 
Used for Scientific or Educational Purposes 
[497/2013] and the Government Decree on 
the Protection of Animals Used for Scientific 
or Educational Purposes). The clinical study 
design in publication III was approved by the 
HUH Medical Ethics Committee.
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The effects of nigral injections CDNF and 
GDNF were studied with repeated 
apomorphine-induced rotations (Figure 7A). 
The number of apomorphine-induced 
contralateral rotations were similar at 2 and 
4 weeks after 6-OHDA injection but before 
NTF injections between study groups 
(ANOVA F(6,82)=0.9282, p=0.479 2 weeks 
and F[6,82]=0.605, p=0.725 at 4 weeks, all 
post hoc Dunnett tests p>0.7). 
A single intranigral infusion of CDNF at four 
weeks after 6-OHDA lesion at any of the 
doses (1, 3.3, 10, 33, or 100 µg) did not 
produce any consistent effect on the drug-
induced rotation behavior when compared to 
the vehicle only (Figure 7B; 6–16 weeks 𝜒2(6) 
= 13.4–16.3, p = 0.012–0.038, all post hoc 
tests p > 0.6, across weeks 6–16 and all CDNF 
concentrations). A marked reduction in 
Figure 7. Effects of various doses of intranigral CDNF injection in a 6-OHDA MFB lesion. (A) Study design 
of experiment 1: NTFs were administered 4 weeks after 6-OHDA. (B) Evolution of apomorphine-induced 
rotations over time. (C) All apomorphine-induced rotations post-NTF injection compared to rotations at 
4 weeks. (D) Average body weight 1 week after growth factor injection compared to body weight before 
growth factor injection. (E) Tyrosine-hydroxylase-stained striatal optical density of TH+ fibers compared 
to the contralateral side. (F) Substantia nigra TH+ cell numbers compared to the contralateral side. Data 
expressed as mean ± SEM, **p < 0.01, ***p < 0.0001. (Reproduced from Huotarinen et al., Neuroscience 




rotations was seen only with GDNF at 100 µg 
at all time points after NTF injections when 
compared to rotations at 4 weeks (𝜒2(4) = 
12.65, p = 0.13, post hoc weeks 8, 12, and 16 
p = 0.050, 0.008, and 0.020, respectively). At 
12 weeks after 6-OHDA injection, GDNF-
treated (100 µg) rats also rotated significantly 
less when compared to PBS-treated rats 
(Dunnett’s test p=0.0493). (Figure 7B) 
Analyzing the sum of all apomorphine-
induced rotations after the NTF injections, 
CDNF injections of 1 µg and 10 µg reduced 
the apomorphine-induced rotations when 
compared to PBS, although the difference 
was not significant for 10 µg (𝜒2(6) = 54.69, p 
< 0.0001, post hoc 0.0307 and 0.10 
respectively. When the sum of post-NTF 
injection apomorphine-induced rotations was 
compared to weekly rotations at the week 4 
baseline before the NTF injection, the 
apomorphine-induced rotations were 
statistically significantly reduced for CDNF 10 
µg and GDNF 100 µg when compared to PBS 
(Figure 7C; 𝜒2(6) = 63.23, p < 0.0001, post hoc 
p = 0.0016, and p < 0.0001, respectively). 
The GDNF-treated animals experienced a 
transient reduction in body weight at 1 week 
after injection (F[6,82] = 18.623, p < 0.001, 
post hoc GDNF vs. all other groups p < 
0.0001, all other post hoc tests p > 0.9) 
(Figure 7D), but the CDNF-treated animals 
experienced no loss in body weight with any 
of the used doses. CDNF (10, 33, or 100 µg) 
or GDNF (100 µg) did not have an effect on 
the optical density of TH + fibers in the 
striatum (Figure 7E, 𝜒2(4) = 4.53, p = 0.34). 
CDNF (10, 33, or 100 µg) did not have an 
effect on the number of TH+ cells in the SNpc 
(Figure 7F[3,44] = 0.056, p = 0.982) when NTF 
was given four weeks after the 6-OHDA 
lesion. 
Similarly, trying to improve the effect of 
intranigral CDNF 10 µg or GDNF 10 µg by 
earlier injections at one week after the 6-
OHDA MFB did not improve the results. No 
Figure 8: A) Study design of experiment 2 for testing intranigral CDNF 10 µg given 1 week after 6-
OHDA. B) Apomorphine-induced contralateral rotations. C) Tyrosine-hydroxylase-stained striatal 
optical density of TH+ fibers compared to contralateral side. D) TH+ cell count compared to the 
contralateral non-lesioned site. Data expressed as mean +/- SEM 




decrease was observed in apomorphine-
induced contralateral rotations at 3, 7, or 9 
weeks when compared to vehicle (Figure 8B; 
p > 0.50 at all time points). The optical 
density of TH-stained striata also remained 
similar with all treatments (Figure 8C; 𝜒 2(2) = 
0.29, p = 0.86) after these earlier injections. 
The SNpc also showed no difference in TH+ 
cells (Figure 8D; 𝜒 2(2) = 2.48, p = 0.29). 
 
5.3 The effect of CDNF on the 
antiparkinsonian effect of STN HFS  
 
Amphetamine-induced ipsilateral rotations 
were used to assign the 6-OHDA lesioned rats 
into similar groups (𝜒2(3) = 1.90, p = 0.59) 
before CDNF injection and STN electrode 
implantations. The response to STN HFS was 
tested repeatedly with cylinder tests (Figure 
9A). 
The stimulation amplitudes used throughout 
the study for the control group (PBS + STN 
HFS) and the study group (CDNF + STN HFS) 
were: low stimulation 106.3 µA vs. 146.2 µA 
(U = 130.5, p = 0.030) and high stimulation 
181.3 µA vs. 250 µA (p=0.029). For the CDNF 
+STN HFS group, the stimulation currents 
were: low stimulation 146.2 µA and high 
stimulation 250 µA. Both stimulation 
amplitudes were used on consecutive days 
after baseline test without stimulation, to 
test for improvement in front limb use in all 
rats. Both stimulation amplitudes improved 
the use of the contralateral front limb in the 
cylinder test at all time points (p<0.001), 
except for control group at week 1 (𝜒2(2) = 
5.56, p = 0.062) and week 5 (𝜒2(2) = 5.73, p = 
0.057). 
 
A cross-sectional analysis comparing CDNF vs. 
PBS treated animals within individual weeks 
revealed no differences in the contralateral 
front limb use in the cylinder tests at any of 
the time points. However, comparing front 
limb use at week 2 and 3 to week 1 revealed 
that only CDNF co-treated rats used the 
contralateral front limb at these stimulation 
time points. This effect was not seen with 
rats receiving PBS in any of the study 
conditions: no stimulation, low stimulation or 
high stimulation (Figure 9B-C; t-test week 2 
p=0.0603 and p=0.252 week 3; p= 0.0719 and 
p = 0.0722, respectively, for low and high 
stimulation). This effect was statistically 
significant only when week 2 and week 3 
time points were analyzed together and 
compared to week 1 baseline (no stimulation 
-11.94 SD 22.82 vs. 6.98 SD 19.13, p=0.0073; 
low stimulation -6.01 SD 25.25 vs. 15.05 SD 
23.74 p=0.0125 and high stimulation 20.24 
SD 27.17 vs. 40.53 SD 29.45 p=0.0377 
respectively). At all time points, the 
stimulation-induced dyskinesias were similar 
(Figure 3D, t-test p=0.304–0.908). 
 
The combination of CDNF and STN HFS led to 
higher levels of striatal TH+ staining when 
compared to rats treated with PBS and STN 
HFS (Figure 9E-F,  t-test p=0.0347). However, 
this finding was not further supported by the 
striatal DAT stainings or nigral counts of TH+ 
cells (Figure 9G, t-test p=0.251). HPLC also 
did not show any difference in striatal DA 
(Figure 9H; ANOVA F(3,14)=0.830, p=0.499)., 
DOPAC (ANOVA F(3,14)=0.830, p=0.499, 5-HT 
concentrations or DOPAC/DA ratio (Figure 9I, 
ANOVA F(3,14)=0.830, p=0.499). No 
differences were noted in behavioral tests or 
HPLC analysis in the control rats without 
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5.4 The effect of the combination of 
CDNF and STNL 
 
Amphetamine-induced rotations were used 
to verify 6-OHDA lesioning and to balance the 
study groups before the CDNF injections and 
STN lesioning (ANOVA F[3,52]=0.007, 
p=0.999).The behavioral effect was tested 
with repeated cylinder apomorphine-induced 
rotation tests. (Figure 10A). Ten rats were 
excluded from the analyses due to 
macroscopic lesions (1 mm or over) in the 
subthalamic area or the thalamus. 
 
STN lesioning with ibotenic acid combined 
with intranigral CDNF reduced apomorphine-
induced rotations at 4 weeks when compared 
to a double sham treatment (PBS + PBS). 
Neither of the treatments alone had this 
effect (Figure 10D, F[3,41] = 3.853, p = 0.16, 
post hoc Tukey for CDNF + STNL vs. PBS + PBS 
p = 0.014). This effect was not carried over to 
week 7 time point, although the STNL + CDNF 
treated animals rotated the least, albeit this 
was not statistically significant (𝜒2 [3] = 6.2, p 
= 0.10). Similarly, neither of the treatments 
alone improved the contralateral front limb 
use over the double sham treatment. By 
contrast, the combination of STNL and CDNF 
improved contralateral front limb use in the 
cylinder test (Figure 10B-C). This effect was 
seen at week 1 both when analyzing all 
touches (𝜒2 (3) = 10.16, p = 0.017, post hoc p 
= 0.047, animals with less than 20 touches on 
the wall were excluded) and first touches (𝜒2 
(3) = 11.02, p = 0.012, post hoc p = 0.012) 
with the cylinder wall. A similar effect was 
seen at week 3 for all touches (𝜒2(3)=15.84, 
p=0.001, post hoc p= 0.011) and first touches 
(animals with under 7 rearings excluded, 
𝜒2(3) = 9.28, p = 0.026, post hoc p = 0.032) 
with the wall. At week 6, the number of 
rearings was low and first touches with the 
cylinder could not be analyzed, but a 
tendency was evident for the CDNF + STNL 
co-treated rats to use the contralateral front 
limb more than the rats that received 
intranigral CDNF and sham STNL when all 
touches with the wall was analyzed (PBS) (𝜒 
2(3) = 6.52, p = 0. 089).  
When the use of contralateral front limb use 
in the cylinder test was compared to baseline 
before intranigral and subthalamic injections, 
only the group of rats that received the 
combination treatment improved at any of 
the time points. This was significant for all 
touches at week 3 (Friedman’s 𝜒 2 = 9.171, p 
= 0.027, post hoc p < 0.001), all other p-
values >0.2) and for first touches at weeks 1 
and 3 (Friedman’s 𝜒2 = 13.91, p = 0.001, post 
hoc p = 0.093 and 0.002, week 6 excluded 
from analysis due to the low number of 
rearings). 
Because some of the rats were excluded 
from the analyses due to inactivity in the 
cylinder test or because of macroscopic STN 
Figure 9: The effects of intranigral (left) CDNF 10 µg combined with subthalamic stimulation (STN HFS). 
A) Study design of experiment 3 for testing the effects intermittent STN HFS combined with CDNF. 
Cylinder tests were done on consecutive days with no stimulation, low stimulation, and high 
stimulation. B) The evolution of right limb use asymmetry when all wall touches were counted for the 
cylinder test compared to baseline (no stimulation) of week 1. C) The evolution of right limb use 
asymmetry when only the first wall touches were counted in the cylinder test compared to baseline 
(no stimulation) of week 1. D) Subthalamic stimulation-induced dyskinesias over time. E) Example of 
TH striatal optical densities at 8 weeks. F) Tyrosine-hydroxylase-stained striatal optical density of TH+ 
fibers compared to contralateral side at 8 weeks. G) TH+ cell counts in the substantia nigra compared 
to contralateral side at 8 weeks. H) DA HPLC results at 4 weeks. I) DOPAC HPLC results at 4 weeks. 
Data expressed as mean +/- SEM, * p<0.05, (*) <0.05 when weeks 2 and 3 were analyzed together. 




region lesions, the data were reanalyzed with 
all animals included, and the same effects 
were seen. The only major change was that 
the decrease in apomorphine-induced 
rotations at week 4 did not reach statistical 
significance in the post hoc test for CDNF + 
STNL treatment over double sham treatment 
when comparing all the study groups against 
each other (F[3,50] = 2.211, p = 0.087, post 
hoc Tukey p = 0.085, Dunnett’s p = 0.049).  
The immunohistochemical analysis revealed 
no difference between the study groups at 8 
weeks after intranigral and subthalamic 
injections. The TH stained striatum optical 
density showed no difference (Figure 10E; 𝜒 
2(3) = 4.347, p = 0.226) nor did the TH+ cell 
count in SNpc (Figure 10F; 𝜒 2(3) = 0.51, p = 
0.92). Striatal dopamine (Figure 10G; 𝜒 2(3) = 
2.04, p = 0.57) and dopamine metabolite 
levels were also similar (DOPAC Figure 10H; 𝜒 
2(3) = 2.97, p = 0.40). The levels of striatal 5-






Figure 10: A) Study design of experiment 4 for testing the combination of intranigral (left) CDNF 
10 µg and STN lesion (STNL). B) Front limb measured by all touches with the wall during rearing 
movements in the cylinder test at baseline before CDNF injections and STN lesioning and at 1, 3, 
and 6 weeks after. C) Front limb measured by first touches with the wall during rearing 
movements in the cylinder test use at baseline before CDNF and STNL and at 1, 3, and 6 weeks 
after. D) The number of apomorphine-induced rotations at 4 and 7 weeks after CDNF and STNL. E) 
Optical density of TH immunohistochemistry of lesioned side compared to the unlesioned side. F) 
The number of TH+ cells in SNpc compared to the unlesioned side. G) HPLC results for percentage 
of dopamine (DA) on the lesioned side compared to the unlesioned side. H) HPLC results for 
percentage of DOPAC on the lesioned side compared to the unlesioned side. Data expressed as 
mean +/- SEM, * p<0.05, **p<0.01 
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6.1 The dyskinetic and anti-akinetic 
effects of experimental STN HFS 
 
An increase in stimulation current increased 
the occurrence of stimulation-induced 
dyskinesias, but a better reversal of 6-OHDA 
induced front limb use deficit, indicating a 
dose response of STN HFS. While the order of 
appearance of stimulation-induced 
dyskinesias has been previously reported,322 
a gradual increase in intensity has not been 
described. Another observation was that 
achieving a significant reversal of front limb 
use deficit required a sufficiently high 
stimulation current to cause transient 
dyskinesias, as shown by the correlation of 
front limb use and stimulation-induced 
dyskinesias. This feature can be used to 
select suitable individual stimulation 
amplitudes for STN HFS. The initial 
stimulation-induced dyskinesias could also 
predict good therapeutic effects of clinical 
STN DBS.226 The gradual appearance of 
stimulation-induced dyskinesias seems also 
to suggest that a grading system, such as the 
one presented here, could be more reliable 
for choosing individual stimulation currents 
when compared to the singular appearance 
of dyskinesia threshold used in some 
previous studies322or the same current used 
for all animals.351 The use of orofacial 
dyskinesias seemed not to have any 
additional benefit and these dyskinesias were 
also difficult to score reliably from videos. 
Orofacial dyskinesias have also been 
suggested to be mediated by different 
mechanisms than other dyskinesias.322,352 
This suggests that orofacial dyskinesias 
should perhaps be excluded from the analysis 
of STN HFS-induced dyskinesias or they 
should be analyzed separately. Occasionally, 
STN HFS also induced hind-limb and, rarely, 
ipsilateral front-limb dyskinesias, which could 
be explained by somatotopy of the STN and 
may therefore be related to the exact 
electrode location in the subthalamic 
region.353 The stimulation-induced 
dyskinesias seen in experimental STN HFS do 
not necessarily replicate the situation in 
clinical STN DBS, because of cross-species 
differences in anatomy, electrode 
configuration, and stimulation timespan. 
 
Interestingly, although front limb use in the 
cylinder test measured by first and all 
touches with the cylinder wall showed good 
correlation, the beneficial effect on the first 
touches with the wall was seen only with the 
higher stimulation amplitude. This suggests 
that the first touch with the wall is a more 
robust phenomenon, perhaps reflecting the 
movement initiation deficit related to 
dopamine depletion and PD. However, the 
improvement in front limb use when all 
touches with the wall were analyzed even 
with the lower stimulation amplitude 
suggests that this is a more sensitive 
measure. Using both methods during analysis 
of the cylinder test is supported by our data 
as this will allow acquisition of a more robust 
and sensitive measure when analyzing 
experimental treatments, as opposed to 
using only one or the other, as has been done 
in some previous studies.106,351 An additional 
benefit of using both measures might be 
seen during repeated cylinder tests, as some 
rats become less active and rear less and 
other rats might be so inactive that the use of 
only the first touches becomes statistically 
unreliable because of the low number of 
observations. Some of these rats could still 
be included in the analysis by using all 
touches with the wall to analyze the front 
limb use, thereby reducing the number of 
animals required. Since changes in the front 
limb use during stimulation with the lower 
amplitude were seen only when analyzing all 
touches, our data suggest using both 
measures to ensure that subtler effects are 
not missed. An additional benefit of 
developing the analysis of cylinder test data 
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is that the cylinder test does not require 
pharmacological stimulation, such as the 
apomorphine or amphetamine used in the 
rotation test. The reversal of front limb use in 
the cylinder test reflects reversal 
bradykinesia, as is seen in clinical PD with 
STN DBS 
 
All the electrodes were found in the 
subthalamic area in the STN or in the 
immediate vicinity and no difference was 
observed in the level of stimulation-induced 
dyskinesias or the reversal of front limb use 
deficit. The stimulation current spreads from 
the active electrode contact to the adjacent 
brain tissue, where a 1 mm distance exists 
between the two contacts in the electrode. 
This suggests that the zona incerta (ZI) 
stimulation might explain the good effect 
achieved with electrode tips outside the STN, 
as also clinical benefit has also been reported 
following ZI stimulation. Some clinical studies 
also suggest that the ZI might be a better 
target than the STN for DBS for PD.255 These 
findings support that animals in the 
experimental setting should not be included 
in or excluded from the final analysis based 
only on behavioral data or electrode tip 
anatomic location; instead, both measures 
should be taken into account. 
 
6.2 Intranigral CDNF in a late-stage PD 
model 
 
In the rat MFB 6-OHDA model of advanced 
PD, which produces a very severe 
dopaminergic lesion,354 no consistent 
reduction was observed in apomorphine-
induced rotations by intranigral CDNF alone 
given at various doses 4 weeks after 6-OHDA 
injection or by 10 µg CDNF given one week 
earlier after 6-OHDA injection. The trial 
replicated the results of a very large dose of 
100 µg GDNF by Hoffer et al.355 without 
concomitant increase in striatal TH.356 
Nevertheless, a small putative effect of 10 µg 
CDNF was revealed by analyzing all the post-
NTF apomorphine rotations together, but this 
did not correlate with rescue of TH positive 
neurites in the striatum or TH positive cells in 
SNpc. Interestingly, treatment with the 100 
µg GDNF led to a transient decrease in body 
weight,355,357,358 suggesting an overall 
negative effect of GDNF on animal welfare 
when compared to CDNF, which caused no 
drop in body weight at any of the trialed 
doses. 
 
Unlike in previous studies using less severe 
models and mainly striatal NTF injections,359-
361 no effect was observed when CDNF alone 
was given intranigrally. This is in line with the 
fact that the striatum is almost completely 
devoid of TH positive neurites 5 years after 
PD diagnosis11 and, correspondingly, some 
neuroprotective effect has been reported 
only in patients with disease durations of less 
than five years.15 NTF-induced 
neuroprotection is suggested to require 
viable dopamine neurons in the SNpc.362 
However, since the accuracy of the initial PD 
diagnosis is low,38 a follow-up period of at 
least 5 years has been suggested before 
invasive treatments to rule out patients with 
atypical PD. 12 More recently, a 
recommendation was made for consideration 
of invasive treatments earlier in the course of 
disease.201 The lack of a good effect could be 
explained by the choice of an intranigral 
injection site, since striatal injections have 
previously been found effective. However, 
striatally injected CDNF is also transported to 
the SNpc.363 The poor results in the clinical 
trials might be explained by insufficient 
diffusion363 of NTFs in the larger human 
striatum, as an increase in TH-positive fibers 
has been found around the injection sites in 
post-mortem samples.364 This implies that, 
despite our mostly negative results with 
intranigral injections, the SNpc might have 
some favorable aspects as an NTF injection 
target as it is smaller and easier to cover with 




6.3 CDNF and acute STN HFS 
 
In the 6-OHDA MFB model, STN HFS 
ameliorated 6-OHDA-related motor deficits in 
rats that received intranigral injection of 
either PBS or CDNF. Despite the lack of a 
statistically significant difference in 
contralateral front limb use when comparing 
the groups at respective weeks, the effect of 
STN HFS was transiently increased at two and 
three weeks after CDNF injection when 
compared to the first week after 
implantation. A tendency to improve tyrosine 
hydroxylase levels in the striatum was also 
evident after 8 weeks, which, disappointingly, 
was not statistically significant and was not 
replicated by an increase in DAT. However, 
behavioral NTF effects might not completely 
depend on the restoration of dopaminergic 
terminals or neurons.365 These putative 
changes in front limb use seen in the cylinder 
tests might reflect the potential of similar 
combinations of CDNF and STN DBS for 
added benefits in treatment of bradykinesia. 
 
6.4 Combined CDNF and STNL 
 
The combination of a STN lesion and CDNF 
alleviated parkinsonian motor deficits, as 
measured by two different behavioral tests 
and the effects were not seen with either 
treatment alone. No clear biochemical effect 
was seen in the striatal density of tyrosine 
hydroxylase-positive fibers or nigral TH-
positive cells or dopamine and its 
metabolites, but a trend was evident for an 
overall CDNF effect on striatal TH levels. 
Previous reports have shown that CDNF can 
produce a partial reversal of the behavioral 
defects in the 6-OHDA hemiparkinsonian rat 
without changes in TH or monoamine 
transmitter levels365 and that the correlation 
between IHC-verified striatal TH-deficits and 
apomorphine-induced rotations is low.66 
 
A positive interaction is evident in the 
behavioral tests. Apomorphine-induced 
rotations provide a crude measure of a 
possible benefit, but the behavior is 
produced by artificial pharmacological 
stimulation, so it might not reflect the 
situation in clinical PD. However, a similar 
result was seen with the cylinder test, which 
provides a more natural and also a more 
clinically relevant measure of the beneficial 
effects of reducing bradykinesia. The results 
should be viewed as preliminary and require 
verification in different PD models, and with 
other behavioral tests, preferably also by 
other groups and with other NTFs. The effect 
might be neuroprotective or 
neurorestorative, or, alternatively, the 
combination might also act solely on a level 
of symptom control. Although our 
experiments did not address the mechanism 
of the effect, previous studies have shown a 
synergy for the combination of CDNF and 
GDNF332 or MANF333, and the NTF-like 
properties of trkB signaling292 and BDNF 
induction324 might explain some of the 
perceived effects. 
 
These data show only a transient effect of a 
single infusion of CDNF, whereas clinical trials 
have used either AAV constructs366 or chronic 
administration of NTFs367. Additionally, STNL 
and STN HFS have both shared and distinct 
effects281. Unfortunately, the observed 
effects seen in the present study were of 
relatively short term, so future studies should 
assess the effects of longer term CDNF 
treatments in combination with DBS models. 
 
In clinically advanced PD, the prospect of 
neurorestoration is quite low49, so the fact 
that the synergistic effect does not rely on 
the regeneration capability of dopamine 
system may be beneficial. Our results this 
suggest that NTFs delivered to the SNpc, 
together with STN DBS, might have additional 
benefits as a treatment for clinical PD. 
However, additional animal experiments are 
needed before planning clinical studies to 




stimulation amplitude for all animals in the 
experiment, the high variability of individual 
responses better supports the use of 
individually tailored stimulation amplitudes. 
However, since the optimal target for animal 
STN stimulation is not completely known, 
conducting studies that compare small 
variations in the subthalamic targeting with 
various electrodes would be reasonable, 
provided the accuracy of animal stereotaxy 
used is precise. 
 
Similarly, despite considerable previous 
research, the optimal target for clinical STN 
DBS is still under debate. The continuous 
improvements in imaging methods, operating 
techniques, and stimulation hardware will 
ensure that this question will continue to be 
an interesting, if controversial, research 
subject for the foreseeable future. Our data 
show a positive treatment response coming 
from a large subthalamic area, which also 
suggests that future clinical studies should 
report the electrode locations, as this is 
disappointingly not often done. One of the 
major limitations of the clinical data is that 
electrode locations were defined using 
almost immediate postoperative imaging, 
which is subject to error. This encourages the 
use of either delayed CTs at one month or 
later or the more widely available 
intraoperative MRI to achieve higher 
precision in electrode location definition. 
Additionally, the analysis of clinical data 
highlights the problems of statistical analysis 
of electrode locations. The effect of electrode 
location on motor symptoms and side effects 
could be better analyzed if the statistical 
methods used allow for analyses in 3D spaces 
or at least at the distance of the electrodes to 
neuroanatomically meaningful structures and 
not simply the orthogonal axes of the 
stereotactic space. 
 
Furthermore, neither STN DBS nor any other 
currently widely available therapies can alter 
the course of clinical PD. NTFs are among 
therapies being studied to provide a disease-
course altering therapy in PD. However, as 
discussed above, in practice, these therapies 
seem often to be implemented in clinical 
situations where the degeneration of the 
dopamine system has progressed so far that 
the possibility for neurorestoration seems 
low. One solution for this is the suggestion 
that both DBS and NTF therapies be offered 
earlier in the course of the disease, and this is 
supported at least in part by the data 
presented here. Additionally, myriad possible 
reasons exist for the previous failures of 
clinical NTF trials. One reason, without 
question, is the fact that, as in our 
experiments, the experimental PD is often 
based on neurotoxin models that do not 
reflect all aspects of clinical PD. The use of a 
amore biologically valid α-synuclein model 
with LB and LN accumulation could provide a 
better testing ground for future 
neuroprotective and neurorestorative 
therapies. In addition, the customary 
protocol is to test promising disease-course 
altering therapies in models with relatively 
modest levels of dopamine degeneration. 
This can perhaps explain some of the 
disappointments in clinical trials and future 
studies should strive to achieve experimental 
neuroprotection and neurorestoration in 
animal models that are compatible with 
advanced PD where, in general, a practical 
possibility exists to use invasive treatments.  
 
Another possibility is that nearly complete 
loss of the dopamine phenotype impairs the 
possibility of neuroprotection and 
neurorestoration altogether. This implies that 
achieving success in the search of disease-
course altering therapies will require reliable 
early diagnosis of neurodegenerative 
diseases. For PD, neuroprotection could 
possibly be achieved in the premotor phase 
of the disease, when the dopamine system is 
still quite viable. Together with previous 
data, our results suggest that successful 
neuroprotection in PD requires the use of 
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several strategies in experimental studies, 
clinical studies, and timing of treatments. 
Especially in the more advanced phases of 
PD, no single treatment alone is likely to 
provide a complete solution. Therefore, 
combinations of neuroprotective/restorative 
and symptomatic treatments should be 






The main objectives of this work were to 
further describe the effects of STN DBS in 
clinical PD, to compare different methods of 
analyzing electrode location, to further 
analyze the behavioral response of STN DBS 
in an animal model, and to study the effect of 
the combination of CDNF and STN DBS in an 
experimental animal model of PD that shows 
dopaminergic degeneration levels 
corresponding to late-stage real-world 
human patients.  
 
The main conclusions are: 
1) Correct electrode placement should be 
defined both behaviorally and histologically 
in rat STN DBS. Tailoring the behavioral 
response quite effectively is possible using 
individually chosen stimulation amplitudes in 
experimental studies. Conducting behavioral 
tests with several amplitudes can improve 
the sensitivity and reliability of the analysis. 
 
2) STN DBS and CDNF have an additive 
synergy seen in behavioral tests in a 
hemiparkinsonian rat model corresponding 
to late-stage PD. However, these results 
should be viewed as preliminary and should 
be tested with other disease models and 
NTFs. The inefficacy of CDNF alone in an 
animal model with near complete dopamine 
depletion suggests that NTFs should be 
studied earlier in clinical PD. This thesis 
provides first supportive evidence that one 
possible solution to overcome the inefficacy 
of NTFs in clinical trials could be offering 
NTFs simultaneously with STN DBS, as these 
therapies seem to have a positive interaction. 
If nigral injections of NTF are confirmed in 
future studies to have this interaction, this 
raises the possibility of providing both NTF 
therapy and STN DBS through similar 
neurosurgical approaches. 
 
3) The data show that although electrode 
location might affect long-term clinical 
efficiency of STN DBS, the anatomical area of 
beneficial effect seems to be large. This 
suggests that some differences in clinical 
studies of STN DBS might be explained by 
subtle differences in electrode positioning, 
which is often omitted from data analysis. 
Defining the electrode location is also 
possible using multiple methods, which can 
improve reliability. The direct visualization of 
the STN is possible using 1.5T MRI, although 
indirect methods using midcommissural 
point and nucleus ruber seem to be more 
reliable. Electrode locations should be 
reported in future clinical studies of STN DBS, 
preferably determined by a combination of 
different methods. Our data also provide 
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